Xintela AB (XINT) - Total Assets
Based on the latest financial reports, Xintela AB (XINT) holds total assets worth Skr9.08 Million SEK (≈ $976.72K USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Xintela AB (XINT) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
Xintela AB - Total Assets Trend (2013–2024)
This chart illustrates how Xintela AB's total assets have evolved over time, based on quarterly financial data. See XINT net asset value for net asset value and shareholders' equity analysis.
Xintela AB - Asset Composition Analysis
Current Asset Composition (December 2024)
Xintela AB's total assets of Skr9.08 Million consist of 96.8% current assets and 3.2% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr16.68 Million | 67.3% |
| Accounts Receivable | Skr1.36 Million | 5.5% |
| Inventory | Skr715.00K | 2.9% |
| Property, Plant & Equipment | Skr785.00K | 3.2% |
| Intangible Assets | Skr0.00 | 0.0% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how Xintela AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see XINT market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Xintela AB's current assets represent 96.8% of total assets in 2024, an increase from 36.7% in 2013.
- Cash Position: Cash and equivalents constituted 67.3% of total assets in 2024, up from 33.4% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2013.
- Asset Diversification: The largest asset category is cash and equivalents at 67.3% of total assets.
Xintela AB Competitors by Total Assets
Key competitors of Xintela AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Syndax Pharmaceuticals Inc
NASDAQ:SNDX
|
USA | $472.67 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $506.75 Million |
|
Chengdu Kanghua Biological Products
SHE:300841
|
China | CN¥3.94 Billion |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.84 Billion |
Xintela AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.23 | 0.21 | 1.80 |
| Quick Ratio | 0.23 | 0.19 | 1.80 |
| Cash Ratio | 0.09 | 0.04 | 0.00 |
| Working Capital | Skr-28.31 Million | Skr-26.60 Million | Skr16.77 Million |
Xintela AB - Advanced Valuation Insights
This section examines the relationship between Xintela AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 18.96 |
| Latest Market Cap to Assets Ratio | 0.55 |
| Asset Growth Rate (YoY) | 34.8% |
| Total Assets | Skr24.80 Million |
| Market Capitalization | $13.70 Million USD |
Valuation Analysis
Below Book Valuation: The market values Xintela AB's assets below their book value (0.55x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Xintela AB's assets grew by 34.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Xintela AB (2013–2024)
The table below shows the annual total assets of Xintela AB from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Skr24.80 Million ≈ $2.67 Million |
+34.81% |
| 2023-12-31 | Skr18.39 Million ≈ $1.98 Million |
-24.97% |
| 2022-12-31 | Skr24.52 Million ≈ $2.64 Million |
-0.91% |
| 2021-12-31 | Skr24.74 Million ≈ $2.66 Million |
-49.00% |
| 2020-12-31 | Skr48.51 Million ≈ $5.22 Million |
+183.82% |
| 2019-12-31 | Skr17.09 Million ≈ $1.84 Million |
-65.62% |
| 2018-12-31 | Skr49.71 Million ≈ $5.35 Million |
+73.92% |
| 2017-12-31 | Skr28.59 Million ≈ $3.08 Million |
+19.86% |
| 2016-12-31 | Skr23.85 Million ≈ $2.57 Million |
+124.52% |
| 2015-12-31 | Skr10.62 Million ≈ $1.14 Million |
+1.20% |
| 2014-12-31 | Skr10.50 Million ≈ $1.13 Million |
+48.16% |
| 2013-12-31 | Skr7.08 Million ≈ $762.38K |
-- |
About Xintela AB
Xintela AB (publ), a biopharma company, develops medical products in the field of stem cell therapy and targeted cancer therapy. The company's stem cell products include XSTEM, which is in Phase I/IIa clinical development for the treatment of knee osteoarthritis, as well as in clinical study for the treatment of difficult-to-heal leg ulcers, acute respiratory distress syndrome, and other indicati… Read more